Corrigendum
In the February 2007 issue, the following text on page 90 was printed incorrectly: βIn an open-label study of 104 patients with euvolemic hyponatremia, conivaptan was administered as an intravenous loading dose of 20 mg over 30 min followed by continuous infusion of 40 mg/day or 80 mg/day for 4 days. In the 40 mg/day group, a serum [Na+] increase of β₯6 mmol/l was attained in 68% of patients compared with 88% in the 80 mg/day group.56β
The correct text is as follows: βIn an open-label study of 104 patients with euvolemic hyponatremia, conivaptan was administered as an intravenous loading dose of 20 mg over 30 min followed by continuous infusion of 20 mg/day or 40 mg/day for 4 days. In the 20 mg/day group, a serum [Na+] increase of β₯6 mmol/l was attained in 91% of patients, and in 73% of patients in the 40 mg/day group.69β
References
Verbalis JG et al. (2004) Novel vasopressin V1a and V2 antagonist conivaptan increases serum sodium concentration and effective water clearance in hyponatremia. J Am Soc Nephrol 15: 356A
Vaprisol package insert (2006) Astellas Pharma US, Inc., Deerfield, IL
Additional information
The online version of the original article can be found at 10.1038/ncpneph0401
Rights and permissions
About this article
Cite this article
Chen, S., Jalandhara, N. & Batlle, D. Erratum: Evaluation and management of hyponatremia: an emerging role for vasopressin receptor antagonists. Nat Rev Nephrol 3, 233 (2007). https://doi.org/10.1038/ncpneph0450
Issue date:
DOI: https://doi.org/10.1038/ncpneph0450
